tbuckley/cabot-search huggingface dataset:
ATIM-26. INTERIM RESULTS OF THE EXTENSION PHASE OF A PHASE I/IIA TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM)
Authors: Patrick Wen, David Reardon, Eudocia Lee, Fabio Iwamoto, David Anderson, Francisco Diaz-Mitoma, Andrew Lassman
Journal: Neuro-Oncology (2019)

Abstract Cytomegalovirus (CMV) antigens have been reported in over 90% of GBM tumors. CD4+and CD8+T cells are most frequently directed against the gB and pp65 antigens, respectively, and are immunogenic targets in a CMV-based GBM vaccine. We have initiated a phase I/IIa clinical trial for patients with recurrent GBM using gB/pp65 enveloped virus-like particles (eVLPs) formulated with GM-CSF and administered intradermally. In phase I, eligible patients were age 18–70 with Karnofsky Performance Status at least 70, normal end-organ function, on stable or decreasing corticosteroids of at most 4mg dexamethasone (or equivalent), with recurrent GBM following any standard initial therapy and any number of recurrences of any size. Patients were vaccinated monthly until tumor progression, with immune-monitoring performed 2 weeks after each vaccination and MRI exams every 6 weeks. The primary endpoint was safety/tolerability and secondarily to assess immunogenicity. Three vaccine doses (0.4µg, 2µg, and 10µg pp65) were evaluated with 6 patients in each cohort, and the DSMB identified no DLTs or safety concerns with any of the doses. The highest 10µg dose was chosen for the Phase IIa extension phase of the trial based on stable disease (3 months or longer) observed in 3/6 patients, which correlated with vaccine-induced IFN-γ-secreting T cell responses against CMV. Enrollment in phase IIa of the trial, which is designed to explore initial potential efficacy signals in an additional 10 patients that receive the optimal 10µg dose of vaccine, is expected in June 2019 and includes the additional requirements of unifocal, measurable enhancing tumor 1–3 cm across at first recurrence and no prior immunotherapy. Patients will be vaccinated monthly until clinical progression. Tumor responses and associated immunological biomarkers will be presented, and are expected to include initial data for all 10 patients.
Bleeding Control Training for the Lay Public: Keep It Simple
Authors: Eileen M. Bulger, Lenworth Jacobs, Ronald M. Stewart
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)
Authors: Amy E. DeZern, Marianna Zahurak, Javier Bolanos-Meade, Richard J. Jones
Journal: Blood (2019)
Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy
Authors: Andrew Hau, Tong Zhu, Rengang Wang, Megan Lau, Lingna Li, Xiaoqing Li, Yingqing Sun, Ernest Kovacs, Alisher Khasanov, Dalun Deng, Zheng Yan, Robert D. Knight, Gunnar F. Kaufmann, Henry Ji, Hui Li, Hong Zhang
Journal: Blood (2019)
The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies
Authors: Alba Rodríguez García, María Linares, Nicolas Mennesson, Alfredo Pérez-Revilla, Ricardo Sanchez, Alejandra Leivas, Rafael Alonso Fernández, Edith Bigot-Corbel, Sylvie Hermouet, Joaquin Martinez-Lopez
Journal: Blood (2019)
CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy
Authors: Jacopo Mariotti, Stefania Bramanti, Raynier Devillier, Barbara Sarina, Sabine Furst, Angela Granata, Valerio Maisano, Thomas Pagliardini, Chiara De Philippis, Catherine Faucher, Samia Harbi, Christian Chabannon, Carmelo Carlo-Stella, Reda Bouabdallah, Armando Santoro, Didier Blaise, Luca Castagna
Journal: Blood (2019)
Antidepressant Drugs and Liver Damage
Authors: H. B. Kidd
Journal: BMJ (1964)

MMICABLJOURNALDr. Dintenfass has shown, I think conclu- sively, that this elastic property of cartilage is as operative during motion as during rest, and that it is ancillary to the lubricant func- tion of the synovial fluid.His theory com- pletes my own and supplies that evidence I was unable to provide.My reason for stressing all this is that during moderate or quick motion, anyway, there will be some flow of the lubricant synovia between the fixed and moving sur- faces because of that adhesion of the fluid to both these surfaces implied (though not sufficiently stressed) in my own writing as well as by C. W. McCutchen's theory.5This calls for a streamlining of the internal sur- face of the joint.My main contention has always been that the general and particular internal mechanisms of the synovial joints are to assist, rather than hinder, such a streamlining.It is a unifying concept of articular structure and the only one that appears to embrace all and not merely some of the facts of anatomy and function.The term " elastohydrodynamic " expresses suc- cinctly how a hydrodynamic lubrication is achieved in joints.-Iam, etc.,
Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation
Authors: Maria Stamouli, Ioannis Tsonis, Konstantinos Gkirkas, Christina Economopoulou, Thomas Thomopoulos, Anna Paisiou, Nikolaos Siafakas, Spyridon Pournaras, Anastasia Antoniadou, Aggeliki Karagiannidi, Joseph Meletiadis, Dimitra Kavatha, George Vassilopoulos, Stavros Gigantes, Ioannis Baltadakis, Evgenios Goussetis, Dimitrios Karakasis, Panagiotis Tsirigotis
Journal: Blood (2019)
RNA-binding protein isoforms ZAP-S and ZAP-L have distinct antiviral and immune resolution functions
Authors: Johannes Schwerk, Frank W. Soveg, Andrew P. Ryan, Kerri R. Thomas, Lauren D. Hatfield, Snehal Ozarkar, Adriana Forero, Alison M. Kell, Justin A. Roby, Lomon So, Jennifer L. Hyde, Michael Gale, Matthew D. Daugherty, Ram Savan
Journal: Nature Immunology (2019)
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial
Authors: Uma Borate, Amy S. Ruppert, Fei Yang, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Amy Burd, Dean Pavlick, Luke Juckett, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Gary J. Schiller, William Blum, Tibor Kovacsovics, Mark Litzow, James M. Foran, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Ashley Owen Yocum, Mona Stefanos, Brian J. Druker, John C. Byrd, Ross L. Levine, Alice S. Mims
Journal: Blood (2019)
Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review
Authors: Zunairah Shah, Syeda Sabeeka Batool, Hafiz Muhammad Fazeel, Mustafa Nadeem Malik, Maryam Sadiq, Syeda Fatima Hassan, Tariq Iqtidar Sadiq Syed, Syed Maaz Abdullah, Nisma Javed, Aqsa Ashraf, Arafat Ali Ali Farooqui, Muhammad Abdullah Yousaf, Muhaddis Ejaz Ahmad, Marium Ghani, Arshia Akbar, Faiz Anwer
Journal: Blood (2019)
Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax
Authors: Piers Blombery, Ella Thompson, Tamia Nguyen, Xiangting Chen, Michelle McBean, Richard W Birkinshaw, Peter E Czabotar, Rachel Thijssen, Mary Ann Anderson, John F. Seymour, David Alan Westerman, David C.S. Huang, Andrew W. Roberts
Journal: Blood (2019)
Different Lifestyle Interventions in Adults From Underserved Communities
Authors: Rodrigo Fernandez-Jimenez, Risa Jaslow, Sameer Bansilal, Raquel Diaz-Munoz, Monali Fatterpekar, Maribel Santana, Andrea Clarke-Littman, Jacqueline Latina, Ana V. Soto, Christopher A. Hill, Mohamed Al-Kazaz, Rajeev Samtani, Rajesh Vedanthan, Chiara Giannarelli, Jason C. Kovacic, Emilia Bagiella, Andrew Kasarskis, Zahi A. Fayad, Valentin Fuster
Journal: Journal of the American College of Cardiology (2019)

The current trends of unhealthy lifestyle behaviors in underserved communities are disturbing. Thus, effective health promotion strategies constitute an unmet need.The purpose of this study was to assess the impact of 2 different lifestyle interventions on parents/caregivers of children attending preschools in a socioeconomically disadvantaged community.The FAMILIA (Family-Based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health) study is a cluster-randomized trial involving 15 Head Start preschools in Harlem, New York. Schools, and their children's parents/caregivers, were randomized to receive either an "individual-focused" or "peer-to-peer-based" lifestyle intervention program for 12 months or control. The primary outcome was the change from baseline to 12 months in a composite health score related to blood pressure, exercise, weight, alimentation, and tobacco (Fuster-BEWAT Score [FBS]), ranging from 0 to 15 (ideal health = 15). To assess the sustainability of the intervention, this study evaluated the change of FBS at 24 months. Main pre-specified secondary outcomes included changes in FBS subcomponents and the effect of the knowledge of presence of atherosclerosis as assessed by bilateral carotid/femoral vascular ultrasound. Mixed-effects models were used to test for intervention effects.A total of 635 parents/caregivers were enrolled: mean age 38 ± 11 years, 83% women, 57% Hispanic/Latino, 31% African American, and a baseline FBS of 9.3 ± 2.4 points. The mean within-group change in FBS from baseline to 12 months was ∼0.20 points in all groups, with no overall between-group differences. However, high-adherence participants to the intervention exhibited a greater change in FBS than their low-adherence counterparts: 0.30 points (95% confidence interval: 0.03 to 0.57; p = 0.027) versus 0.00 points (95% confidence interval: -0.43 to 0.43; p = 1.0), respectively. Furthermore, the knowledge by the participant of the presence of atherosclerosis significantly boosted the intervention effects. Similar results were sustained at 24 months.Although overall significant differences were not observed between intervention and control groups, the FAMILIA trial highlights that high adherence rates to lifestyle interventions may improve health outcomes. It also suggests a potential contributory role of the presentation of atherosclerosis pictures, providing helpful information to improve future lifestyle interventions in adults.
Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia
Authors: Yuya Kishida, Yuho Najima, Yuki Otsuka, Kenya Toma, Atsushi Wada, Hiroto Adachi, Ryosuke Konuma, Tatsuya Konishi, Akihito Nagata, Yuta Yamada, Ryohei Nagata, Atsushi Marumo, Junichi Mukae, Yuma Noguchi, Kyoko Inamoto, Takashi Toya, Aiko Igarashi, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi, Noriko Doki
Journal: Blood (2019)
EPID-12. IMPACT OF RACE AND GEOGRAPHIC LOCATION ON IDH MUTATIONS AND GLIOBLASTOMA SURVIVAL
Authors: Ryan McCormack, Ping Zhu, Takeshi Takayasu, Gabriella Hines, Hussein Zeineddine, Nitin Tandon, Sergio Moreno Jimenez, Alberto Gonzalez, Leomar Y Ballester, Yoshua Esquenazi
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor of the central nervous system with a 5-year survival of &lt; 5%. Population studies have demonstrated that among all ethnicities, non-Hispanic whites (NHW) have the worst prognosis; however, differences within the oncogenome based on ethnicity have not been assessed. We utilized the Texas Cancer Registry (TCR) for population-based analysis including 4,134 GBM patients between the years of 1995 to 2013 with 75.6% NHW and 16.5% Hispanics. In accordance with previously published findings, within the TCR we detected a 12% relative survival improvement in Hispanics compared to NHW when controlling for known survival mediators including age, resection, chemotherapy, and radiation. In order to assess for oncogenic differences, we utilized a prospectively maintained database of 257 GBM patients within the city of Houston, TX (14.9% Hispanic) and 48 GBM patients from the National Institute of Neurology and Neurosurgery in Mexico City, Mexico (100% Hispanic) to assess for oncogenomic differences attributable to ethnicity. Next generation sequencing of GBM within the Houston cohort, for 315 tumor-related genes, identified no significant differences in genomic alterations owing to ethnicity. However, when we compared the multigenerational, mixed-heritage Hispanics present in the Houston cohort to the Mexico cohort (Sanger sequencing), a significant difference was found in the frequency of IDH1and IDH2mutations (29.8 % Mexico Hispanics, 7.9% Houston Hispanics; p=0.014). In particular, the rate of IDH2mutations is significantly enriched in the Mexico population (19%) when compared to the Houston population (0%) or to previously published rates of IDH2 mutations in GBM (~3%). Ultimately, these findings highlight the need for multiethnic trial enrollment as well as the need for improved testing of IDH2 mutations in patients of distinct ethnicities. Future studies are needed to identify the mechanisms promoting the increased frequency of IDH2 mutations in Mexican Hispanics.
The New Dentistry: A Phase of Preventive Medicine. Six Lowell Lectures.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CBMT-28. FATTY ACID OXIDATION PROVIDES METABOLIC PLASTICITY TO MAINTAIN GROWTH IN THE DYNAMIC MICROENVIRONMENT OF GLIOBLASTOMA
Authors: Shiva Kant, Pravin Kesarwani, Antony Prabhu, Stewart Graham, Katie Buelow, Ichiro Nakano, Prakash Chinnaiyan
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma represents an aggressive, primary brain tumor with limited treatment options. Despite advances in molecularly characterizing glioblastoma, metabolic alterations driving its aggressive phenotype are only beginning to be recognized. Integrative cross-platform analyses coupling global metabolomic and gene expression profiling identified alterations in fatty acid β-oxidation (FAO) as a key metabolic node differentiating glioblastoma from low-grade astrocytoma, which was defined by an accumulation of acylcarnitines. Metabolic heterogeneity was observed within glioblastoma that could further define tumors as FAO ‘high’ and ‘low’, which were enriched with mesenchymal and proneural subtypes of glioblastoma, respectively. These findings were metabolomically and functionally recapitulated in molecular subtype-specific preclinical models, with the majority of baseline mitochondrial oxygen consumption being a result of enhanced FAO in these cells. The biologic consequence of enhanced FAO in glioblastoma is directly dependent upon tumor microenvironment. FAO serves as a metabolic cue to drive proliferation in a β-HB/GPR109A/cAMP-dependent autocrine manner in nutrient favorable conditions while providing an efficient, alternate source of ATP only in nutrient unfavorable conditions. Accordingly, inhibiting FAO alone in glioblastoma cells with etomoxir only led to modest anti-proliferative activity and minimal cytotoxicity. However, rational combinatorial strategies designed to target the dynamic roles FAO plays in gliomagenesis resulted in metabolic synthetic lethality in glioblastoma. Specifically, dual targeting of FAO (etomoxir) and glycolysis (2DG) resulted in robust energetic stress, necroptosis mediated cell death, and a significant improvement in survival in an orthotopic glioblastoma mouse model. In summary, we identified FAO as a dominant metabolic node in glioblastoma that provides metabolic plasticity, allowing these cells to adapt to their dynamic microenvironment. Combinatorial strategies designed to target these diverse roles FAO plays in gliomagenesis offers therapeutic potential in glioblastoma.
Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality
Authors: Ko Ko Ko Maung, Mohammad Chaudhry, Yi Ren, Sin-Ho Jung, Kristi M. Romero, Kelly Corbet, Nelson J. Chao, Taewoong Choi, Anna Mae Diehl, Louis F. Diehl, Cristina Gasparetto, Mitchell E. Horwitz, Gwynn D. Long, Richard D. Lopez, David A. Rizzieri, Stefanie Sarantopoulos, Keith Sullivan, Mustafa R. Bashir, Anthony D. Sung
Journal: Blood (2019)
HDGF overexpression enhances the tumorigenicity of hepatocellular carcinoma
Authors: Hsiao-Mei Kuo, Li-Feng Liu, Chi-hao Chen, Ming-Hong Tai
Journal: Cancer Research (2008)

4550  Hepatoma-derived growth factor (HDGF) is a novel growth factor identified from conditioned medium of human hepatoma cells. HDGF upregulation was associated with poor outcome and tumor progression in hepatocellular carcinoma (HCC). However, the mechanism underlying HDGF overexpression during HCC progression remains unclear. To investigated the effects of HDGF expression during liver carcinogenesis. Besides, the stimulatory effects of exogenous HDGF on cellular proliferation, migration and aortic ring of endothelial cells. Enhanced HDGF expression and secretion by adenovirus gene delivery significantly enhanced proliferation, migration and anchorage-independent growth of SK-Hep-1 cells. In contrast, reduction of endogenous HDGF expression by gene delivery of HDGF antisense vector attenuated the oncogenic properties in SK-Hep-1 cells. In xenografted HCC model, implantation of Ad-HDGF-transduced SK-Hep-1 cells promoted the tumor progression in SCID mice whereas implantation of HDGF-knockdown SK-Hep-1 cells caused retarded tumor growth. Histological analysis revealed that an increase in CD31-positive blood vessels and VEGF was observed in Ad-HDGF-transduced tumors while HDGF-knockdown led to attenuated neovascularization in hepatoma. Exogenous HDGF induces activation ROS (reactive oxygen species) product then enhanced NFκB, Cox-2, PGE2 and VEGF. In summary, HDGF overexpression enhanced the tumorigenicity of hepatoma cells via NFκB/VEGF pathway, thereby promoting HCC progression.
Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease
Authors: Maryam Sarraf Yazdy, Umair Jarral, Chao Yin, Frank Kuhr, Allison P. Jacob, Bruce D. Cheson
Journal: Blood (2019)
Abstract 147: AED on the Fly: A Drone Delivery Feasibility Study for Rural and Remote Out-Of-Hospital Cardiac Arrest
Authors: Sheldon Cheskes, Paul Snobelen, Shelley McLeod, Steven Brooks, Christian Vaillancourt, Timothy Chan, Katie N Dainty, Mike Nolan
Journal: Circulation (2019)

Introduction: Time-to-treatment plays a pivotal role in survival from sudden cardiac arrest (SCA). Every minute of delay in defibrillation results in a 7-10% reduction in survival. Time to defibrillation is particularly problematic in rural and remote regions, where traditional bystander and EMS response is often prolonged and automated external defibrillators (AED) are often not available. The objective of this study was to examine the feasibility of a novel AED drone delivery method for rural and remote SCA. A secondary objective was to compare times between AED drone delivery and ambulance response to various mock SCA resuscitations. Methods: We conducted four simulations to determine the feasibility of AED drone delivery to mock SCA resuscitations in a rural public setting in Ontario, Canada. During each simulation, a “mock” call was placed to 911 and a single AED drone and an ambulance were simultaneously dispatched from the same location to a pre-determined destination for a mock SCA. Once on scene, trained first responders retrieved the AED from the drone and initiated resuscitative efforts on a manikin until paramedics arrived. Results: The distance from dispatch location to scene varied from 6.6 kms to 8.8 kms. Mean (SD) response time from 911 call to arrive at mock code location was 11.2 (1.0) for EMS compared to 8.1 (0.1) minutes for AED drone delivery. In all four simulations, the AED drone arrived before EMS, ranging from 2.1 minutes to 4.4 minutes faster. Mean (SD) time from AED removal from drone to application to manikin by a trained responder was 35(5) sec. No difficulties were encountered in drone activation by dispatch, drone lift off, landing or removal of the AED from the drone by responders. Conclusions: This implementation study suggests AED drone delivery is feasible with improvements in response time during a simulated SCA scenario. These results suggest the potential for AED drone delivery to decrease time to first defibrillation in rural and remote communities. Further research is required to determine the appropriate distance for drone delivery of an AED in an integrated EMS system as well as optimal strategies to simplify bystander application of a drone delivered AED.